Extended Data Fig. 9: Characterization of CD4 CTLs primed by LMP1-transduced A20 cells.
From: Mechanism of EBV inducing anti-tumour immunity and its therapeutic use
a, Cytotoxicity of CD4 CTLs primed by LMP1-A20 cells against the B cell lymphoma line BCL1 at an E:T ratio of 50:1, in the presence of MHC-II blocking antibody or isotype control antibody. b, Representative FACS analysis of intra-tumoral CD45.1+ adoptive CD4 cells (excluding FOXP3+) recovered from A20-bearing mice (CD45.2+) treated as in Fig. 3g–i. All mice are on the BALB/c background. Statistics and reproducibility are presented in the Supplementary Information.
